The median survival rate of ibrutinib in the treatment of slow gonorrhea is about 8.5 years.
As a selective TBK tyrosine kinase inhibitor, ibrutinib primarily inhibits the B-cell tumor survival signaling pathway, which further mediates the effects on B-cell proliferation, migration, and adhesion.
With ibrutinib treatment alone, 40% of patients experienced remission after 2 months of treatment, and the remission rate increased with the duration of treatment. And the effect is more significant with the prolongation of treatment. However, disease progression exists in some patients.
Ibrutinib combined with other drugs in the treatment of chronic gonorrhea has also achieved certain results, ibrutinib combined with rituximab program for the treatment of chronic gonorrhea is better than the effect of single use, can improve the overall effectiveness of the treatment, prolong the progression-free survival rate of patients.
Adverse reactions include rash, fever, diarrhea, etc. It is contraindicated in patients with severe hepatic or renal insufficiency as well as allergy to the product.
The effectiveness and safety of ibrutinib treatment is greatly guaranteed, and the prognosis of timely treatment will be relatively good, you should go to the hospital in a timely manner under the guidance of a physician for treatment.